September 1, 2022
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
August 31, 2022
Revolution Medicines to Participate in Upcoming Investor Conferences
August 9, 2022
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
July 28, 2022
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
July 22, 2022
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 19, 2022
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
July 19, 2022
Revolution Medicines Announces Commencement of Public Offering of Common Stock
July 13, 2022
Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
June 28, 2022
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
June 9, 2022
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference